3,4-dimethyl-6-oxo-N-(3-propan-2-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-1H-pyridazine-5-carboxamide
C16H22N6O2 — CID 86772498
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3,4-dimethyl-6-oxo-N-(3-propan-2-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-1H-pyridazine-5-carboxamide
3,4-dimethyl-6-oxo-N-(3-propan-2-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-1H-pyridazine-5-carboxamide (PubChem CID 86772498) has the molecular formula C16H22N6O2 and a molecular weight of 330.39 g/mol. Its IUPAC name is 3,4-dimethyl-6-oxo-N-(3-propan-2-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-1H-pyridazine-5-carboxamide.
Molecular Properties
| Compound Name | 3,4-dimethyl-6-oxo-N-(3-propan-2-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-1H-pyridazine-5-carboxamide |
|---|---|
| PubChem CID | 86772498 |
| Molecular Formula | C16H22N6O2 |
| Molecular Weight | 330.39 g/mol |
| Exact Mass | 330.18 |
| IUPAC Name | 3,4-dimethyl-6-oxo-N-(3-propan-2-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-1H-pyridazine-5-carboxamide |
| SMILES | Cc1n[nH]c(=O)c(C(=O)NC2CCc3nnc(C(C)C)n3C2)c1C |
| InChI | InChI=1S/C16H22N6O2/c1-8(2)14-20-19-12-6-5-11(7-22(12)14)17-15(23)13-9(3)10(4)18-21-16(13)24/h8,11H,5-7H2,1-4H3,(H,17,23)(H,21,24) |
| InChIKey | DHJLOYFATXOOPM-UHFFFAOYSA-N |
| XLogP | 0.85 |
| TPSA | 105.56 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 24 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 330.39 |
| LogP ≤ 5 | 0.85 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 86772498 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.